Helicobacter pylori and Antibacterial Agents

André. Bryskier; John Lowther; Catherine Couturier

doi:10.1128/9781555815929.ch40

Chapter 40 : Helicobacter pylori and Antibacterial Agents

Authors: André. Bryskier, John Lowther, Catherine Couturier

Content Type: Reference

Publication Year: 2005

Category: Bacterial Pathogenesis

Book DOI: 10.1128/9781555815929

Chapter DOI: 10.1128/9781555815929.ch40

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Helicobacter pylori and Antibacterial Agents, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap40-1.gif /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap40-2.gif

Abstract:

The recognition of Helicobacter pylori as an etiological agent of gastric peptic ulcer, gastric adenocarcinoma, and mucosaassociated lymphoid tissue lymphoma is one of the most important advances made in gastroenterology in the past 50 years. Eradication therapy is recommended for infected persons who develop peptic ulcer disease or gastric lymphoma or who are beginning long-term treatment with nonsteroidal anti-inflammatory drugs. Among the few conserved families of efflux systems associated with bacterial resistance to antibacterial agents, one is widespread among gram-negative bacilli: the RND family. In Tartu, Estonia, 56 patients suffering from H. pylori infections were enrolled for testing of the susceptibility of H. pylori clinical isolates to antibacterial agents. There are few data regarding the H. pyloriresistance rate in the United States. The frequency of primary clarithromycin and metronidazole resistance among patients enrolled in different geographical areas in the U.S.-based clinical trials between 1993 and 1999 was assessed by MIC determinations using E-test. The rate of resistance to amoxicillin and tetracycline in this study among H. pylori isolates was low. The marked decrease of metronidazole in gastric juice after repeated administration of omeprazole is explained by the elevation of gastric pH induced by omeprazole. Ciprofloxacin was administered as a single dose of 500mg in 15 patients undergoing biopsies. Ciprofloxacin levels ranged from 1.5 to 1,762 mg/kg. Optimal concentrations were obtained after 1 h of dosing and reached 500 mg/kg. The in vitro activities of various antibacterial agents against H. pylori were assessed, including linezolid, dalfopristin-quinupristin, mupirocin, aminoglycosides, and fosfomycin.

Citation: Bryskier A, Lowther J, Couturier C. 2005. Helicobacter pylori and Antibacterial Agents, p 1011-1054. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch40

Key Concept Ranking

Antibacterial Agents: 0.52055156
Mitogen-Activated Protein Kinase Pathway: 0.4404034
Tumor Necrosis Factor alpha: 0.4323581

0.52055156

Highlighted Text: Show | Hide

Full text loading...

Figures

Helicobacter pylori and Antibacterial Agents

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815929.ch40-1,webId=/content/author/10.1128/9781555815929.ch40-1,properties={foaf_givenname=André., foaf_name=André. Bryskier, foaf_surname=Bryskier}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815929.ch40-2,webId=/content/author/10.1128/9781555815929.ch40-2,properties={foaf_givenname=John, foaf_name=John Lowther, foaf_surname=Lowther}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815929.ch40-3,webId=/content/author/10.1128/9781555815929.ch40-3,properties={foaf_givenname=Catherine, foaf_name=Catherine Couturier, foaf_surname=Couturier}]]

/content/10.1128/9781555815929.ch40.ch40fig1

Figure 1

Proton pump inhibitors

10.1128/9781555815929/f1022-01_thmb.gif

10.1128/9781555815929/f1022-01.gif

Figure 1

Proton pump inhibitors

/content/10.1128/9781555815929.ch40.ch40fig2

Figure 2

Ebrotidine

10.1128/9781555815929/f1024-01_thmb.gif

10.1128/9781555815929/f1024-01.gif

Figure 2

Ebrotidine

/content/10.1128/9781555815929.ch40.ch40fig3

Figure 3

5-Hydroxyquinoline

10.1128/9781555815929/f1024-02_thmb.gif

10.1128/9781555815929/f1024-02.gif

Figure 3

5-Hydroxyquinoline

/content/10.1128/9781555815929.ch40.ch40fig4

Figure 4

FR-180102

10.1128/9781555815929/f1024-03_thmb.gif

10.1128/9781555815929/f1024-03.gif

Figure 4

FR-180102

/content/10.1128/9781555815929.ch40.ch40fig5

Figure 5

Piperidyl derivatives

10.1128/9781555815929/f1025-01_thmb.gif

10.1128/9781555815929/f1025-01.gif

Figure 5

Piperidyl derivatives

/content/10.1128/9781555815929.ch40.ch40fig6

Figure 6

Guanidine analogs

10.1128/9781555815929/f1025-02_thmb.gif

10.1128/9781555815929/f1025-02.gif

Figure 6

Guanidine analogs

/content/10.1128/9781555815929.ch40.ch40fig7

Figure 7

FR-145175

10.1128/9781555815929/f1026-01_thmb.gif

10.1128/9781555815929/f1026-01.gif

Figure 7

FR-145175

/content/10.1128/9781555815929.ch40.ch40fig8

Figure 8

Triazolyl cephems

10.1128/9781555815929/f1029-01_thmb.gif

10.1128/9781555815929/f1029-01.gif

Figure 8

Triazolyl cephems

/content/10.1128/9781555815929.ch40.ch40fig9

Figure 9

Anti-H. pylori action of cephems

10.1128/9781555815929/f1029-02_thmb.gif

10.1128/9781555815929/f1029-02.gif

Figure 9

Anti-H. pylori action of cephems

/content/10.1128/9781555815929.ch40.ch40fig10

Figure 10

Thiazolyl cephems

10.1128/9781555815929/f1030-01_thmb.gif

10.1128/9781555815929/f1030-01.gif

Figure 10

Thiazolyl cephems

/content/10.1128/9781555815929.ch40.ch40fig11

Figure 11

FR-182024

10.1128/9781555815929/f1030-02_thmb.gif

10.1128/9781555815929/f1030-02.gif

Figure 11

FR-182024

/content/10.1128/9781555815929.ch40.ch40fig12

Figure 12

Macrolides with anti-H. pylori activity

10.1128/9781555815929/f1034-01_thmb.gif

10.1128/9781555815929/f1034-01.gif

Figure 12

Macrolides with anti-H. pylori activity

/content/10.1128/9781555815929.ch40.ch40fig13

Figure 13

Telithromycin

10.1128/9781555815929/f1035-01_thmb.gif

10.1128/9781555815929/f1035-01.gif

Figure 13

Telithromycin

/content/10.1128/9781555815929.ch40.ch40fig14

Figure 14

Cethromycin

10.1128/9781555815929/f1036-01_thmb.gif

10.1128/9781555815929/f1036-01.gif

Figure 14

Cethromycin

/content/10.1128/9781555815929.ch40.ch40fig15

Figure 15

NADH oxidase in metronidazole-resistant H. pylori

10.1128/9781555815929/f1039-01_thmb.gif

10.1128/9781555815929/f1039-01.gif

Figure 15

NADH oxidase in metronidazole-resistant H. pylori

/content/10.1128/9781555815929.ch40.ch40fig16

Figure 16

Bicyclic fluoroquinolone with anti-H. pylori activity

10.1128/9781555815929/f1041-01_thmb.gif

10.1128/9781555815929/f1041-01.gif

Figure 16

Bicyclic fluoroquinolone with anti-H. pylori activity

/content/10.1128/9781555815929.ch40.ch40fig17

Figure 17

Y-26611

10.1128/9781555815929/f1041-02_thmb.gif

10.1128/9781555815929/f1041-02.gif

Figure 17

Y-26611

/content/10.1128/9781555815929.ch40.ch40fig18

Figure 18

Y-34867

10.1128/9781555815929/f1042-01_thmb.gif

10.1128/9781555815929/f1042-01.gif

Figure 18

Y-34867

/content/10.1128/9781555815929.ch40.ch40fig19

Figure 19

Structure and activity of natural quinolones against H. pylori

10.1128/9781555815929/f1043-01_thmb.gif

10.1128/9781555815929/f1043-01.gif

Figure 19

Structure and activity of natural quinolones against H. pylori

/content/10.1128/9781555815929.ch40.ch40fig20

Figure 20

Rotenoids

10.1128/9781555815929/f1045-01_thmb.gif

10.1128/9781555815929/f1045-01.gif

Figure 20

Rotenoids

/content/10.1128/9781555815929.ch40.ch40fig21

Figure 21

TAK-083

10.1128/9781555815929/f1045-02_thmb.gif

10.1128/9781555815929/f1045-02.gif

Figure 21

TAK-083

/content/10.1128/9781555815929.ch40.ch40fig22

Figure 22

BAS-118

10.1128/9781555815929/f1045-03_thmb.gif

10.1128/9781555815929/f1045-03.gif

Figure 22

BAS-118

/content/10.1128/9781555815929.ch40.ch40fig23

Figure 23

Catechin derivatives

10.1128/9781555815929/f1046-01_thmb.gif

10.1128/9781555815929/f1046-01.gif

Figure 23

Catechin derivatives

/content/10.1128/9781555815929.ch40.ch40fig24

Figure 24

Pyloricidin derivatives

10.1128/9781555815929/f1047-01_thmb.gif

10.1128/9781555815929/f1047-01.gif

Figure 24

Pyloricidin derivatives

/content/10.1128/9781555815929.ch40.ch40fig25

Figure 25

Nitazoxanide

10.1128/9781555815929/f1048-01_thmb.gif

10.1128/9781555815929/f1048-01.gif

Figure 25

Nitazoxanide

/content/10.1128/9781555815929.ch40.ch40fig26

Figure 26

Pyrrazolyl derivatives: inhibition of DHODase of H. pylori

10.1128/9781555815929/f1049-01_thmb.gif

10.1128/9781555815929/f1049-01.gif

Figure 26

Pyrrazolyl derivatives: inhibition of DHODase of H. pylori

/content/10.1128/9781555815929.ch40.ch40fig27

Figure 27

Plautonol

10.1128/9781555815929/f1049-02_thmb.gif

10.1128/9781555815929/f1049-02.gif

Figure 27

Plautonol

/content/10.1128/9781555815929.ch40.ch40fig28

Figure 28

Thiourea analogs of plautonol with H. pylori activity

10.1128/9781555815929/f1050-01_thmb.gif

10.1128/9781555815929/f1050-01.gif

Figure 28

Thiourea analogs of plautonol with H. pylori activity

/content/10.1128/9781555815929.ch40.ch40fig29

Figure 29

Diol plaunotol analogs

10.1128/9781555815929/f1050-02_thmb.gif

10.1128/9781555815929/f1050-02.gif

Figure 29

Diol plaunotol analogs

/content/10.1128/9781555815929.ch40.ch40fig30

Figure 30

Cabreuvin

10.1128/9781555815929/f1050-03_thmb.gif

10.1128/9781555815929/f1050-03.gif

Figure 30

Cabreuvin

/content/10.1128/9781555815929.ch40.ch40fig31

Figure 31

Calvatic acid

10.1128/9781555815929/f1051-01_thmb.gif

10.1128/9781555815929/f1051-01.gif

Figure 31

Calvatic acid

/content/10.1128/9781555815929.ch40.ch40fig32

Figure 32

Sulforaphane

10.1128/9781555815929/f1051-02_thmb.gif

10.1128/9781555815929/f1051-02.gif

Figure 32

Sulforaphane

References

/content/book/10.1128/9781555815929.ch40

1. Adachi K,, Ishihara S,, Hashimoto T,, Hirakawa K,, Niigaki M,, Takashima T,, Kaji T,, et al, 2000, Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen, Aliment Pharmacol Ther, 14, 919– 922.

2. Ahmed A,, Smoot D,, Liyttleton G,, Tackey R,, Walters CS,, Kashanchi P,, Atten CR,, Ashktorab H, 2000, Helicobacter pylori inhibits gastric cell cycle programme, Microbes Infect, 2, 1159– 1169.

3. Akada JK,, Shirai M,, Faji K,, Okita K,, Nakazawa T, 1999, In vitro anti- Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657, Antimicrob Agents Chemother, 43, 1072– 1076.

4. Andersen LP,, Wadström T, 2001, Basic bacteriology and culture, p 27– 38, in Mosley HLT,, Mencz GL,, Hazzell SH, ed, Helicobacter pylori: Physiology and Genetics, ASM Press, Washington, D.C.

5. Ando R,, Kawamura M,, Chiba N, 2001, 3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents, J Med Chem, 44, 4468– 4474.

6. Anglada L,, Marquez M,, Sacristan A,, Ortiz JA, 1988, Inhibitors of gastric acid secretions, N-sulphonyl formamidines in a series of a new histamine H2 receptors antagonists, Eur J Med Chem, 23, 97– 100.

7. Bizzazero G, 1893, Über die Schlauch formeigen Drusen des magen Darmkanals und die bezienhungen ihres Epiteloz zu dem oberflachen Epithel der Schleimhaut, Arch Mikr Anat, 42, 82.

8. Black JW,, Owen DA,, Parsons ME, 1997, An analysis of the depressor responses to histamine in the cat and dog: involvement of both H1- and H2-receptors. 1975, Br J Pharmacol, 120 (4 Suppl), 420– 425.

9. Blaser MJ,, Berg DE, 2001, Helicobacter pylori, genetic diversity and risk of human disease, J Clin Investig, 107, 767– 773.

10. Bryskier A,, Belfiglio S, 1999, Cephalosporins, p 703– 748, in Yu VL,, Merignan CT Jr,, Barriè re SL, ed, Oral Antimicrobial Therapy and Vaccines, Williams & Wilkins, Baltimore, Md.

11. Copeland RA,, Davis JP,, Dowling RL,, Lombardo D,, Murphy KB,, Patterson TA, 1995, Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme, Arch Biochem Biophys, 323, 79– 86.

12. Copeland RA,, Marcin Keviciene J,, Haque TS,, Kopcho LM, et al, 2000, Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis, J Biol Chem, 275, 33373– 33378.

13. Covacci A,, Telford JL,, del Giudice G,, Parsonnet J,, Rappuoli R, 1999, Helicobacter pylori virulence and genetic geography, Science, 284, 1329– 1353.

14. Cussac V,, Ferrero RL,, Labigne A, 1992, Expression of Helicobacter pylori urease genes in Escherichia coli grown under nitrogen-limiting conditions, J Bacteriol, 174, 2466– 2473.

15. de Bernard M,, Arico B,, Papini E,, Rizzuto R,, Grandi G,, Rappuoli R,, et al, 1997, Helicobacter pylori toxin VacA induces vacuole formation by acting in the cell cytosol, Mol Microbiol, 26, 665– 674.

16. Dekker KA,, Inagaki T,, Gootz TD,, Huang LH,, Kojima Y,, Kohlbrenner WE,, Matsunaga Y,, McGuirk PR,, Nomura E,, Sakakibara T,, Sakemi S,, Suzuki Y,, Yamauchi Y,, Kojima N, 1998, New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity, taxonomy of producing strains, fermentation, isolation, structural elucidation and biological activation, J Antibiot, 51, 145– 152.

17. Dent JC,, McNulty CAM,, Uff JC,, Wilkinson SP,, Gear MWL, 1987, Spiral organisms in the gastric antrum, Lancet, ii, 96.

18. Dore MP,, Graham DY,, Sepulveda AR, 1998, PBD D, a novel penicillin-binding protein, is involved in amoxicillin-resistant Helicobacter pylori, Gastroenterology, 114–A-109. (Abstract.)

19. Dore MP,, Graham DY,, Sepulveda AR,, Realdi G,, Osato MS, 1999, Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins, Antimicrob Agents Chemother, 43, 1803– 1804.

20. Dubois A,, Berg DE,, Incecik ET,, Fiala N,, Heman-Ackah LM,, Del Valle J,, Yang M,, Winck HP,, Perez-Perez GI,, Blaser MJ, 1999, Host specificity of Helicobacter pylori strains and host responses in experimentally challenged non-human primates, Gastroenterology, 116, 90– 96.

21. Dubois A,, Berg DE,, Incecik ET,, Fiala N,, Heman-Ackah LM,, Perez-Perez GI,, Blaser MJ, 1996, Transient and persistent experimental infection of nonhuman primates with Helicobacter pylori: implications for human disease, Infect Immun, 64, 2885– 2891.

22. Dubreuil L,, Houcke I,, Mouton Y,, Rossignol JF, 1996, In vitro evaluation of nitazoxanide and tizoxanide against anaerobes and aerobic organisms, Antimicrob Agents Chemother, 40, 2266– 2270.

23. Dunn BE,, Cohen H,, Blaser MJ, 1997, Helicobacter pylori, Clin Microbiol Rev, 10, 720– 741.

24. Eaton KA,, Radin MJ,, Kramer L,, Wack R,, Sherding R,, Krakowka S,, Morgan DR, 1991, Gastric spiral bacilli in captive cheetahs, Scand J Gastroenterol Suppl, 181, 38– 42.

25. Enroth H,, Engstrand L, 2001, An update on Helicobacter pylori microbiology and infection for the new millennium, Scand J Infect Dis, 33, 163– 174.

26. Ernst PB,, Gold BD, 2000, The disease sprectrum of Helicobacter pylori, the immunopathogenesis of gastroduodenal ulcers and gastric cancer, Annu Rev Microbiol, 54, 615– 640.

27. Fellenius E,, Berglindh T,, Sachs G,, Olbe L,, Elander B,, Sjostrand SE,, Wallmark B, 1981, Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+/K+) ATPase, Nature, 290, 159– 161.

28. Fox JG,, Batchelder M,, Marini R,, Yan L,, Handt L,, Li X,, Shames B,, Hayward A,, Campbell J,, Murphy JC, 1995, Helicobacter pylori- induced gastritis in the domestic cat, Infect Immun, 63, 2674– 2681.

29. Freedberg AS,, Baron LE, 1940, The presence of spirochetes in human gastric mucosa, Am J Dig Dis, 74, 443– 445.

30. Fujimura S,, Kawamura T,, Asib N,, Takahashi H,, Watanabe A, 2000, Helicobacter pylori infection rate in patients treated with rifampicin: eradication effect of rifampicin on Helicobacter pylori, Jpn J Antibiot, 48, 839– 842.

31. Ghiara P,, Marchetti M,, Blaser MJ,, Tummuru MKR,, Cover TL,, Segal ED,, et al, 1995, Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease, Infect Immun, 63, 4154– 4160.

32. Goodwin CS, et al, 1989, Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori and Helicobacter mustelae, respectively, Int J Syst Bacteriol, 39, 397– 405.

33. Gorbach SL, 1990, Bismuth therapy in gastrointestinal diseases, Gastroenterology, 99, 863– 875.

34. Grayson ML,, Eliopoulos GM,, Ferraro MJ,, Moellering RC Jr, 1989, Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents, Eur J Clin Microbiol Infect Dis, 8, 888– 889.

35. Hamasaki N,, Ishi E,, Tominaga K,, Tezuka Y,, Nagaoka T,, Kadota S,, Kuroki T,, Yano I, 2000, Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori in vitro, Microbiol Immunol, 44, 9– 15.

36. Hara Y, Antioxidants in tea and their physiological functions, p 49– 65, in Hiramatsu M et al, ed, Food and Free Radicals, Plenum Press, New York, N.Y.

37. Harris PR,, Mobley HL,, Perez-Perez GL,, Blaser MJ,, Smith PD, 1996, Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory production, Gastroenterology, 111, 419– 425.

38. Heep M,, Beck D,, Bayerdörffer E,, Lehn N, 1999, Rifampin and rifabutin resistance mechanism in Helicobacter pylori, Antimicrob Agents Chemother, 43, 1497– 1499.

39. Heep M,, Odenbreit S,, Beck D,, Decker J,, Prohaska E,, Rieger U,, Lehn N, 2000, Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins, Antimicrob Agents Chemother, 44, 1713– 1715.

40. Higuchi K,, Arakawa T,, Ando K,, Fujiwara Y,, Uchida T,, Kurochi T, 1999, Eradications of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies, Am J Gastroenterol, 94, 1419– 1420.

41. Hirayama F,, Takagi S,, Yakoyama Y,, Iwao E,, Ikeda Y, 1996, Establishment of gastric Helicobacter pylori infection in Mongolian gerbils, J Gastroenterol, 31, suppl 9, 24– 28.

42. Holck S,, Ingeholm P,, Blom J,, Norgaard A,, Elsborg L,, Adamsen S,, Andersen LP, 1997, The histopathology of human gastric mucosa inhibited by Helicobacter heilmannii-leko (Gastrospirillum hominis) organisms including one culturable case, APMIS, 105, 746– 756.

43. Horn J, 2000, The proton pump inhibitors, similarities and differences, Clin Ther, 22, 266– 280.

44. Huang JQ,, Sridhar S,, Chen Y,, Hunt RH, 1998, Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer, Gastroenterology, 114, 1169– 1179.

45. Ikagai H,, Nakae T,, Hara Y,, Shimamura T, 1993, Bactericidal catechins damage the lipid bilayer, Biochim Biophys Acta, 1147, 132– 136.

46. Ito S, 1967, Anatomic structure of the gastric mucosa, p 705– 741, in Code CF, ed, Alimentary Canal, American Physiological Society, Washington, D.C.

47. Iwahi T,, Satoh H,, Nakao M,, Iwasaki T,, Yamazaki T,, Kubo K,, Tamura T,, Imada A, 1991, Lanzoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori, Antimicrob Agents Chemother, 35, 490– 496.

48. Kadota S,, Basnet P,, Ishii E,, Tamura T,, Namba T, 1997, Antibacterial activity of trichorabdal A from Rabdosia trichocarpa against Helicobacter pylori, Zentralbl Bakteriol, 286, 63– 67.

49. Kajima K,, Nakajuma K,, Karata H,, Tabata K,, Utsui Y, 1996, Synthesis of a piperidinomethylthiophene derivative as H2-antagonist with inhibitory activity against Helicobacter pylori, Bioorg Med Chem Lett, 1796– 1798.

50. Kanamuru T,, Nakano Y,, Toyoda Y,, Miyagawa KI,, Tada M,, Kaisho T,, Nakao M, 2001, In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection, Antimicrob Agents Chemother, 45, 2455– 2459.

51. Katsura Y,, Nishino S,, Inoue Y,, Sakane K,, Matsumoto Y,, Morinaga C,, Ishikawa H,, Takasugi H, 2002, Anti-Helicobacter pylori agents. 5. 2-(substituted guanidino)-4-arylthiazoles and aryloxazole analogues, J Med Chem, 45, 143– 150.

52. Katsura Y,, Nishino S,, Ohno M,, Sakane K,, Matsumoto Y,, Morinaga C,, Ishikawa H,, Takasugi H, 1999, Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles, J Med Chem, 42, 2920– 2926.

53. Katsura Y,, Nishino S,, Tomishi T,, Sakane K,, Matsumoto Y,, Ishikawa H,, Takasugi H, 1998, Anti-Helicobacter pylori agents. 2. Structure-activity relationship in a new series of 2-alkylguanidino-4-furylthiazoles, Bioorg Med Chem Lett, 8, 1307– 1312.

54. Katsura Y,, Tomishi T,, Inoue Y,, Sakane K,, Matsumoto Y,, Morinaga C,, Ishikawa H,, Takasugi H, 2000, Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives, J Med Chem, 43, 3315– 3321.

55. Kawakami Y,, Akahane T,, Yamaguchi M,, Oana K,, Takashi Y,, Okimura Y,, Okabe T,, Gotoh A,, Katsuyama T, 2000, In vitro activities of rubeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobial agents against recent clinical isolates of Helicobacter pylori, Antimicrob Agents Chemother, 44, 458– 461.

56. Kidd M,, Modlin IM, 1998, A century of Helicobacter pylori: paradigms lost, paradigms regained, Digestion, 59, 1– 15.

57. Kobayashi I,, Muraoka H,, Hasegawa M,, Saika T,, Nishida M,, Kawamura M,, Ando R, 2002, In vitro anti-Helicobacter pylori activity of BAS-118, a new benzamide derivative, J Antimicrob Chemother, 50, 129– 132.

58. Kobayashi S,, Ishibashi C,, Morita A,, Masuda H,, Ogiso A, 1982, Anti-ulcer activities of (E, Z, E)-7-hydroxymethyl-3,121,15 trimethyl-2,6,10,14-hexadecatetraen-1-01 (CS 684), a new cyclic diterpene alcohol from Thai medicinal plant, on experimental acute gastric and duodenal ulcers, Pharmacometrics, 24, 599– 607.

59. Koga T,, Kawada H,, Utsui Y,, Domon H,, Ischii C,, Yasuda H, 1996, In-vitro and in-vivo antibacterial activity of plaunotol, a cyto-predictive antiulcer agent, against Helicobacter pylori, J Antimicrob Chemother, 37, 919– 929.

60. Koga T,, Watanabe H,, Kawada H,, Takahashi K,, Utsui Y,, Domon H,, Ishii C,, Narita T,, Yasuda H, 1998, Interactions of plaunotol with bacterial membranes, J Antimicrob Chemother, 42, 133– 140.

61. Kogen H,, Tago K,, Arai M,, Minomi E,, Masuda K,, Akiyama T, 1999, A highly stereoselective synthesis of plaunotol and its thiourea derivatives as potent antibacterial agents against Helicobacter pylori, Bioorg Med Chem Lett, 9, 1347– 1350.

62. Kriewitz W, 1906, Über das Auftreten von Spirochäten verschiedene form im Magen hinhält bei Carcinoma ventriculi, Dtsch Med Wochenschr, 32, 872.

63. Lee A,, O’Rourke J,, Corazon de, Ungria M,, Robertson B,, Daskalopoulos G,, Dixon MF, 1997, A standardized mouse model of Helicobacter pylori infection, introducing the Sydney strain, Gastroenterology, 112, 1386– 1397.

64. Loo VG,, Sherman P,, Matlow AG, 1992, Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents, Antimicrob Agents Chemother, 36, 1133– 1135.

65. The Maastricht Consensus, 1997, Current European concepts in the management of Helicobacter pylori infection, report, Gut, 41, 8– 13.

66. Marchetti M,, Arico B,, Burroni D,, Figura N,, Rappuoli R,, Ghiara P, 1995, Development of a mouse model of Helicobacter pylori infection that mimics human disease, Science, 267, 1655– 1658.

67. Marshall BJ,, Warren JR, 1983, Unidentified curved bacilli on gastric epithelium in active chronic gastritis, Lancet, i, 1273– 1275.

68. Matsumoto SY,, Washizuku Y,, Matsumoto Y,, Tanara S,, Ikeda F,, Yokota Y,, Karita M, 1997, Induction of ulceration and severe gastritis in Mongolian gerbil by Helicobacter pylori infection, J Med Microbiol, 46, 391– 397.

69. Matzke M,, Peterson U,, Jaetsch T,, Bartel S,, Schenke T,, et al, 1998, Use of 7(2-oxa-5,8 diazabicyclo [430] non 8-91) quinolone and naphthyridonecarboxytic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal illnesses, patent WO 98-007672-1898.

70. Mauch F,, Bode G,, Malferheiner P, 1993, Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitor, Am J Gastroenterol, 88, 1801– 1802.

71. McGowan CC,, Cover TH,, Blaser MJ, 1994, The protein pump inhibitor omeprazole inhibits survival of Helicobacter pylori by a urease-independent mechanism, Gastroenterology, 107, 738– 743.

72. Mégraud F,, Occhialini A,, Rossignol JF, 1998, Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole, Antimicrob Agents Chemother, 42, 2836– 2840.

73. Melchers K,, Wertzenegger T,, Buhmann A,, Steinhilber W,, Sachs G,, Schafer KP, 1996, Cloning and membrane topology of a P-type ATPase from Helicobacter pylori, J Biol Chem, 271, 456– 457.

74. Nagata K,, Satoh H,, Iwahi T,, Shimoyama T,, Tamura T, 1993, Potent inhibitory action of the gastric pump inhibitor lansoprazole against urease activity of Helicobacter pylori, unique action selective for H. pylori cells, Antimicrob Agents Chemother, 37, 769– 774.

75. Nagata K,, Sone N,, Tamura T, 2001, Inhibitory activities of lansoprazole against respiration in Helicobacter pylori, Antimicrob Agents Chemother, 45, 1522– 1527.

76. NIH Consensus Development Panel, 1994, Helicobacter pylori in peptic ulcer disease, JAMA, 272, 65– 69.

77. Noach LA,, Roef TM,, Tytgat GNJ, 1994, Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa, J Clin Pathol, 47, 699– 704.

78. Ogiso A,, Kitazawa E,, Karabasyashi M,, Sato A,, Takahashi S,, Nogurhi H,, et al, 1978, Isolation and structure of antipeptic ulcer diterpene from Thai medicinal plant, Chem Pharm Bull, 26, 3117– 3123.

79. Ohsaki A,, Takashima J,, Chiba N,, Kawamura M, 1999, Microanalysis of a selective potent anti-Helicobacter pylori compound in a Brazilian medicinal plant, Myroxylon peruiferum, and the activity of analogues, Bioorg Med Chem Lett, 9, 409– 412.

80. On SLW, 2001, Taxonomy of Campylobacter, Arcobacter, Helicobacter and related bacteria, current status, future prospects and immediate concerns, J Appl Microbiol, 90, 1S-15S.

81. O’Toole PW,, Lane MC,, Porowollik S, 2000, Helicobacter pylori mobility, Microbes Infect, 2, 1207– 1214.

82. Parsonnet J,, Shmuely H,, Haggerty T, 1999, Fecal and oral shedding of Helicobacter pylori from healthy infected adults, JAMA, 282, 2240– 2245.

83. Perez-Perez GL,, Gower CB,, Blaser MJ, 1994, Effects of cations on Helicobacter pylori urease activity, release, and stability, Infect Immun, 62, 299– 302.

84. Perri F,, Festa V,, Andricelli A, 1998, Treatment of antibiotic-resistant Helicobacter pylori infection, N Engl J Med, 339, 53.

85. Peterson WL, 1997, The role of antisecretory drugs in the treatment of Helicobacter pylori infection, Aliment Pharmacol Ther, 11, Suppl 1, 21– 25.

86. Piotrowski J,, Piotrowski E,, Slomiany A,, Slomiany BL, 1995, Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine, J Physiol Pharmacol, 46, 463– 469.

87. Piotrowski J,, Slomiany A,, Murty VLN,, Fekete Z,, Slomiany BL, 1991, Inhibition of Helicobacter pylori colonization by sulfated gastric mucin, Biochem Int, 24, 749– 756.

88. Psilogenis M,, Alberico P,, Bianchi G,, Nazzaci M, 1991, Sulglycotide, p 232– 244, in Broga PD, ed, Drugs on Gastroenterology, Raven Press, New York.

89. Rappuoli R,, Lange C,, Censini S,, Covacci A, 1998, Pathogenicity island mediated Helicobacter pylori interaction with the host, Folia Microbiologia, 43, 275– 278.

90. Rautelin H,, Renkonen OV,, Kosunen TU, 1992, In vitro susceptibility of Helicobacter pylori to nitecapone, Eur J Clin Microbiol Infect Dis, 11, 274– 275.

91. Rautelin H,, Vaara M,, Renkonen OV,, Kosanen TU,, Seppäla K, 1992, In vitro activity of antifungal azoles against Helicobacter pylori, Eur J Clin Microbiol Infect Dis, 11, 273– 274.

92. Roine RP,, Salmela KS,, Hook-Nikanne J,, Kosunen TU,, Salaspuro M, 1992, Alcohol dehydrogenase mediated acetalde-hyde production by Helicobacter pylori—a possible mechanism behind gastric injury, Life Sci, 51, 1333– 1337.

93. Shomer NH,, Dangler CA,, Whary MT,, Fox JG, 1998, Experimental Helicobacter pylori infection induces antral gastritis and gastric mucosa-associated lymphoid tissue in guinea pigs, Infect Immun, 66, 2614– 2618.

94. Slomiany BL,, Piotrowski J,, Majka J,, Slomiany A, 1995, Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents, Scand J Gastroenterol, 30 (S210), 82– 84.

95. Slomiany BL,, Piotrowski J,, Slomiany A, 1992, Effect of sucralfate on the degradation of human gastric mucus by Helicobacter pylori protease and lipases, Am J Gastroenterol, 87, 595– 599.

96. Slomiany BL,, Piotrowski J,, Slomiany A, 1997, Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide, Biochem Mol Biol Int, 42, 155– 161.

97. Steer HW,, Colin-Jones DG, 1975, Mucosal changes in gastric ulceration and their response to carbenoxolone sodium, Gut, 16, 590– 597.

98. Takashima J, et al, 2002, Derrisin, a new rotenoid from Derris malaccensis, plain and anti-Helicobacter pylori activity of its related constituents, J Nat Prod, 65, 611– 613.

99. Talley N,, Full-Young C,, Wyatt JMA,, Adam S,, Lau A,, Borody T,, Tseng-Shing C,, Daskofojoloor C,, Cheung K,, Talley XIA, 1998, Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection, Alim Pharmacol Ther, 12, 527– 532.

100. Taylor DN,, Blaser JH, 1991, The epidemiology of Helicobacter infection, Epidemiol Rev, 13, 42– 59.

101. Torello J,, Castillo JR,, Gonzales S,, Mariguez P,, Merino MN,, Jimenez MC, 1998, Liver injury associated with ebrotidine, Methods Finds Exp Clin Pharmacol, 20, Suppl A, abstract 015.

102. Tsuchiya M,, Imamura L,, Park J-B,, Kobashi K, 1995, Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor, Biol Pharm Bull, 18, 1053– 1056.

103. Van Caekenberghe DL,, Breyssens J, 1987, In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis ( C. pylori), Antimicrob Agents Chemother, 31, 1429– 1430.

104. Vandamme P,, Falsen E,, Rossau R,, Hoste B,, Segers P,, Tytgat R,, De Ley J, 1991, Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: emendation of generic descriptions and proposal of Arcobacter gen. nov. Int J Syst Bacteriol, 41, 88– 103.

105. Van Zeneca SJO,, Goldie J,, Hollingworth J, et al, 1992, Secretion of intravenously administered antibiotics in gastric juice, implication for management of H. pylori, J Clin Pathol, 45, 225– 227.

106. Westblom TU,, Duriiex DE, 1991, Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist: implications for treatment of Helicobacter pylori infections, Dig Dis Sci, 36, 25– 28.

107. Wood AJJ, 1995, The treatment of Helicobacter pylori infection in the management of peptic ulcer disease, N Engl J Med, 333, 984– 991.

108. World Health Organization, 1994, International Agency for Research on Cancer Monographs, 61, 177– 220.

109. Xiang Z,, Censini S,, Bayeli PF,, Telford JL,, Figura N,, Rappuoli R,, Covacci A, 1995, Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin, Infect Immun, 63, 94– 98.

110. Yokota K,, Kurebayashi Y,, Takagawa Y,, Hayashi S,, Isogai H,, Isogai E,, Imai K,, Yabana T,, Yachi A,, Oguma K, 1991, Colonization of Helicobacter pylori in the gastric mucosa of Mongolian gerbils, Microbiol Immunol, 35, 473– 480.

111. Yoshida Y,, Barrett D,, Azami H,, Morinaga C,, Matsumoto S,, Matsumoto Y,, Takasugi H, 1999, Studies on anti-Helicobacter pylori agents. Part 1. Benzyloxoisoquinoline derivatives, Bioorg Med Chem, 7, 2647– 2666.

112. Yoshiyama H,, Nakazawa T, 2000, Unique mechanism of Helicobacter pylori for colonizing the gastric mucus, Microbes Infect, 2, 55– 60.

Tables

Helicobacter pylori and Antibacterial Agents

/content/10.1128/9781555815929.ch40.ch40tab1

Table 1

Main Helicobacter species and their hosts a

Table 1

Main Helicobacter species and their hosts a

/content/10.1128/9781555815929.ch40.ch40tab2

Table 2

Virulence factors of H. pylori

Table 2

Virulence factors of H. pylori

/content/10.1128/9781555815929.ch40.ch40tab3

Table 3

E-test methods for H. pylori

Table 3

E-test methods for H. pylori

/content/10.1128/9781555815929.ch40.ch40tab4

Table 4

Influence of pH on anti-H. pylori activities of various antibacterials a

Table 4

Influence of pH on anti-H. pylori activities of various antibacterials a

/content/10.1128/9781555815929.ch40.ch40tab5

Table 5

Zone size for metronidazole against H. pylori

Table 5

Zone size for metronidazole against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab6

Table 6

Table 6 Prevalence of H. pylori resistance in Lisbon, Portugal

Table 6

Table 6 Prevalence of H. pylori resistance in Lisbon, Portugal

/content/10.1128/9781555815929.ch40.ch40tab7

Table 7

Prevalence of H. pylori isolates resistant to antibacterials in the United Kingdom

Table 7

Prevalence of H. pylori isolates resistant to antibacterials in the United Kingdom

/content/10.1128/9781555815929.ch40.ch40tab8

Table 8

Prevalence of H. pylori isolates resistant to antibacterials in England

Table 8

Prevalence of H. pylori isolates resistant to antibacterials in England

/content/10.1128/9781555815929.ch40.ch40tab9

Table 9

H. pylori resistance in children in Belgium

Table 9

H. pylori resistance in children in Belgium

/content/10.1128/9781555815929.ch40.ch40tab10

Table 10

Epidemiological survey in Spain for H. pylori susceptibility in children

Table 10

Epidemiological survey in Spain for H. pylori susceptibility in children

/content/10.1128/9781555815929.ch40.ch40tab11

Table 11

Prevalence (secondary) of H. pylori resistant strains in two geographical areas in Germany

Table 11

Prevalence (secondary) of H. pylori resistant strains in two geographical areas in Germany

/content/10.1128/9781555815929.ch40.ch40tab12

Table 12

Prevalence of H. pylori resistance to metronidazole in Europe from 1990 to 1991

Table 12

Prevalence of H. pylori resistance to metronidazole in Europe from 1990 to 1991

/content/10.1128/9781555815929.ch40.ch40tab13

Table 13

Prevalence of H. pylori resistance to antibacterials in Europe in 1998

Table 13

Prevalence of H. pylori resistance to antibacterials in Europe in 1998

/content/10.1128/9781555815929.ch40.ch40tab14

Table 14

Rate of resistance of H. pylori to clarithromycin (MIC, >1.0 μg/ml) in the United States

Table 14

Rate of resistance of H. pylori to clarithromycin (MIC, >1.0 μg/ml) in the United States

/content/10.1128/9781555815929.ch40.ch40tab15

Table 15

Prevalence of metronidazole and clarithromycin resistance of H. pylori in two areas in Japan

Table 15

Prevalence of metronidazole and clarithromycin resistance of H. pylori in two areas in Japan

/content/10.1128/9781555815929.ch40.ch40tab16

Table 16

Prevalence of H. pylori isolates resistant to antibacterials in Korea

Table 16

Prevalence of H. pylori isolates resistant to antibacterials in Korea

/content/10.1128/9781555815929.ch40.ch40tab17

Table 17

Clarithromycin resistance of H. pylori in Brazil

Table 17

Clarithromycin resistance of H. pylori in Brazil

/content/10.1128/9781555815929.ch40.ch40tab18

Table 18

Prevalence of H. pylori resistance in Lebanon

Table 18

Prevalence of H. pylori resistance in Lebanon

/content/10.1128/9781555815929.ch40.ch40tab19

Table 19

Prevalence of H. pylori resistance in Saudi Arabia

Table 19

Prevalence of H. pylori resistance in Saudi Arabia

/content/10.1128/9781555815929.ch40.ch40tab20

Table 20

In vitro anti-H. pylori activity of bismuth salts (n = 16) a

Table 20

In vitro anti-H. pylori activity of bismuth salts (n = 16) a

/content/10.1128/9781555815929.ch40.ch40tab21

Table 21

Anti-Helicobacter activities of proton pump inhibitors

Table 21

Anti-Helicobacter activities of proton pump inhibitors

/content/10.1128/9781555815929.ch40.ch40tab22

Table 22

Activity against urease (measured by the indophenol method)

Table 22

Activity against urease (measured by the indophenol method)

/content/10.1128/9781555815929.ch40.ch40tab23

Table 23

In vitro activities of H2-antagonists against H. pylori

Table 23

In vitro activities of H2-antagonists against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab24

Table 24

Comparative anti-H. pylori activity of ebrotidine

Table 24

Comparative anti-H. pylori activity of ebrotidine

/content/10.1128/9781555815929.ch40.ch40tab25

Table 25

Comparative anti-H. pylori activity of FR-180102

Table 25

Comparative anti-H. pylori activity of FR-180102

/content/10.1128/9781555815929.ch40.ch40tab26

Table 26

Anti-H. pylori activity of piperidyl derivative a

Table 26

Anti-H. pylori activity of piperidyl derivative a

/content/10.1128/9781555815929.ch40.ch40tab27

Table 27

Anti-H2 activities of guanidino derivatives

Table 27

Anti-H2 activities of guanidino derivatives

/content/10.1128/9781555815929.ch40.ch40tab28

Table 28

Anti-H. pylori activities and anti-H2-receptors of furothiazolyl derivatives

Table 28

Anti-H. pylori activities and anti-H2-receptors of furothiazolyl derivatives

/content/10.1128/9781555815929.ch40.ch40tab29

Table 29

Anti-H2 activity of a pyridyl derivative

Table 29

Anti-H2 activity of a pyridyl derivative

/content/10.1128/9781555815929.ch40.ch40tab30

Table 30

Anti-H. pylori activity of FR-145715

Table 30

Anti-H. pylori activity of FR-145715

/content/10.1128/9781555815929.ch40.ch40tab31

Table 31

Eradication of H. pylori in gnobiotic piglets with FR-145715

Table 31

Eradication of H. pylori in gnobiotic piglets with FR-145715

/content/10.1128/9781555815929.ch40.ch40tab32

Table 32

Amino acid changes in strain 69A (amoxicillin resistant)

Table 32

Amino acid changes in strain 69A (amoxicillin resistant)

/content/10.1128/9781555815929.ch40.ch40tab33

Table 33

Concentrations of amoxicillin and ampicillin in gastric tissue

Table 33

Concentrations of amoxicillin and ampicillin in gastric tissue

/content/10.1128/9781555815929.ch40.ch40tab34

Table 34

Half-lives of degradation of antibacterials at pH 2.0

Table 34

Half-lives of degradation of antibacterials at pH 2.0

/content/10.1128/9781555815929.ch40.ch40tab35

Table 35

Intragastric pH gradient in humans a

Table 35

Intragastric pH gradient in humans a

/content/10.1128/9781555815929.ch40.ch40tab36

Table 36

Amoxicillin concentrations in serum and gastric tissues a

Table 36

Amoxicillin concentrations in serum and gastric tissues a

/content/10.1128/9781555815929.ch40.ch40tab37

Table 37

In vitro activity of FR-182024 against H. pylori isolates

Table 37

In vitro activity of FR-182024 against H. pylori isolates

/content/10.1128/9781555815929.ch40.ch40tab38

Table 38

In vitro activities of β-lactam antibiotics against H. pylori

Table 38

In vitro activities of β-lactam antibiotics against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab39

Table 39

In vitro comparative activities of fropenem and other antibacterials against H. pylori (n = 100)

Table 39

In vitro comparative activities of fropenem and other antibacterials against H. pylori (n = 100)

/content/10.1128/9781555815929.ch40.ch40tab40

Table 40

In vitro activities of macrolides against H. pylori

Table 40

In vitro activities of macrolides against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab41

Table 41

Kinetics of macrolide interaction with H. pylori 70S ribosomes

Table 41

Kinetics of macrolide interaction with H. pylori 70S ribosomes

/content/10.1128/9781555815929.ch40.ch40tab42

Table 42

Frequency of spontaneous mutation in H. pylori

Table 42

Frequency of spontaneous mutation in H. pylori

/content/10.1128/9781555815929.ch40.ch40tab43

Table 43

Correlation between E. coli and H. pylori numeration

Table 43

Correlation between E. coli and H. pylori numeration

/content/10.1128/9781555815929.ch40.ch40tab44

Table 44

Gastric mucosa tissue concentration of roxithromycin

Table 44

Gastric mucosa tissue concentration of roxithromycin

/content/10.1128/9781555815929.ch40.ch40tab45

Table 45

Gastric tissue level of clarithromycin and the main metabolite

Table 45

Gastric tissue level of clarithromycin and the main metabolite

/content/10.1128/9781555815929.ch40.ch40tab46

Table 46

Azithromycin concentrations in gastric juice and tissue

Table 46

Azithromycin concentrations in gastric juice and tissue

/content/10.1128/9781555815929.ch40.ch40tab47

Table 47

Gastric tissue concentration of erythromycin

Table 47

Gastric tissue concentration of erythromycin

/content/10.1128/9781555815929.ch40.ch40tab48

Table 48

In vitro activities of A-69334 and A-70310 against H. pylori

Table 48

In vitro activities of A-69334 and A-70310 against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab49

Table 49

In vitro activity of telithromycin against H. pylori

Table 49

In vitro activity of telithromycin against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab50

Table 50

In vitro activity of telithromycin against clarithromycin-resistant H. pylori

Table 50

In vitro activity of telithromycin against clarithromycin-resistant H. pylori

/content/10.1128/9781555815929.ch40.ch40tab51

Table 51

Influence of pH on determination of MICs for H. pylori

Table 51

Influence of pH on determination of MICs for H. pylori

/content/10.1128/9781555815929.ch40.ch40tab52

Table 52

In vitro activity of ABT-773 against H. pylori

Table 52

In vitro activity of ABT-773 against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab53

Table 53

In vitro activity of ABT-773 against H. pylori isolates resistant to clarithromycin (n = 15)

Table 53

In vitro activity of ABT-773 against H. pylori isolates resistant to clarithromycin (n = 15)

/content/10.1128/9781555815929.ch40.ch40tab54

Table 54

In vitro activities of cyclines against H. pylori

Table 54

In vitro activities of cyclines against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab55

Table 55

In vitro activity of metronidazole against H. pylori

Table 55

In vitro activity of metronidazole against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab56

Table 56

In vitro activity of metronidazole against competent and noncompetent H. pylori strainsa

Table 56

In vitro activity of metronidazole against competent and noncompetent H. pylori strainsa

/content/10.1128/9781555815929.ch40.ch40tab57

Table 57

In vitro activities of nitroimidazole analogs against H. pyloria

Table 57

In vitro activities of nitroimidazole analogs against H. pyloria

/content/10.1128/9781555815929.ch40.ch40tab58

Table 58

Pharmacokinetics of metronidazole in gastric juice with and without omeprazole

Table 58

Pharmacokinetics of metronidazole in gastric juice with and without omeprazole

/content/10.1128/9781555815929.ch40.ch40tab59

Table 59

In vitro activities of quinolones against H. pylori

Table 59

In vitro activities of quinolones against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab60

Table 60

Anti-H. pylori activities of 7-morpholinoquinolones

Table 60

Anti-H. pylori activities of 7-morpholinoquinolones

/content/10.1128/9781555815929.ch40.ch40tab61

Table 61

In vitro activities of ansamycin derivatives

Table 61

In vitro activities of ansamycin derivatives

/content/10.1128/9781555815929.ch40.ch40tab62

Table 62

In vitro activities of rifalazil and KRM-1657

Table 62

In vitro activities of rifalazil and KRM-1657

/content/10.1128/9781555815929.ch40.ch40tab63

Table 63

Bactericidal activities of ansamycins against H. pylori

Table 63

Bactericidal activities of ansamycins against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab64

Table 64

Frequency of mutation induced with ansamycins against H. pylori

Table 64

Frequency of mutation induced with ansamycins against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab65

Table 65

H. pylori: rpoB mutations a

Table 65

H. pylori: rpoB mutations a

/content/10.1128/9781555815929.ch40.ch40tab66

Table 66

In vitro activities of various antibacterials against H. pylori

Table 66

In vitro activities of various antibacterials against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab67

Table 67

In vitro activity of TAK-083 against H. pylori (n = 54)

Table 67

In vitro activity of TAK-083 against H. pylori (n = 54)

/content/10.1128/9781555815929.ch40.ch40tab68

Table 68

In vitro activity of BAS-118 against H. pylori (n = 100)

Table 68

In vitro activity of BAS-118 against H. pylori (n = 100)

/content/10.1128/9781555815929.ch40.ch40tab69

Table 69

In vitro activity of pyloricidin B against H. pylori (n = 50)

Table 69

In vitro activity of pyloricidin B against H. pylori (n = 50)

/content/10.1128/9781555815929.ch40.ch40tab70

Table 70

In vivo activity of pyloricidin B against H. pylori

Table 70

In vivo activity of pyloricidin B against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab71

Table 71

In vitro activities of azole antifungals against H. pylori

Table 71

In vitro activities of azole antifungals against H. pylori

/content/10.1128/9781555815929.ch40.ch40tab72

Table 72

Genes of pyrimidine biosynthesis and salvage pathways a

Table 72

Genes of pyrimidine biosynthesis and salvage pathways a

/content/10.1128/9781555815929.ch40.ch40tab73

Table 73

Anti-H. pylori activities of cytoprotective antiulcer agents (n = 14)

Table 73

Anti-H. pylori activities of cytoprotective antiulcer agents (n = 14)

/content/10.1128/9781555815929.ch40.ch40tab74

Table 74

In vitro activity of sucralfate

Table 74

In vitro activity of sucralfate

/content/10.1128/9781555815929.ch40.ch40tab75

Table 75

In vitro activity of calvatic acid against H. pylori

Table 75

In vitro activity of calvatic acid against H. pylori